Blair William & Co. IL reduced its stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 43.2% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 6,807 shares of the medical instruments supplier’s stock after selling 5,170 shares during the quarter. Blair William & Co. IL’s holdings in LeMaitre Vascular were worth $213,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of LMAT. Columbia Wanger Asset Management LLC increased its position in LeMaitre Vascular by 21.0% during the 1st quarter. Columbia Wanger Asset Management LLC now owns 1,093,903 shares of the medical instruments supplier’s stock valued at $26,943,000 after purchasing an additional 189,608 shares during the period. Conestoga Capital Advisors LLC increased its position in LeMaitre Vascular by 45.8% during the 2nd quarter. Conestoga Capital Advisors LLC now owns 565,069 shares of the medical instruments supplier’s stock valued at $17,641,000 after purchasing an additional 177,379 shares during the period. Bank of New York Mellon Corp increased its position in LeMaitre Vascular by 137.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 210,628 shares of the medical instruments supplier’s stock valued at $6,574,000 after purchasing an additional 122,076 shares during the period. Russell Investments Group Ltd. increased its position in LeMaitre Vascular by 211.2% during the 1st quarter. Russell Investments Group Ltd. now owns 150,413 shares of the medical instruments supplier’s stock valued at $3,705,000 after purchasing an additional 102,078 shares during the period. Finally, Ameriprise Financial Inc. increased its position in LeMaitre Vascular by 52.3% during the 1st quarter. Ameriprise Financial Inc. now owns 201,508 shares of the medical instruments supplier’s stock valued at $4,963,000 after purchasing an additional 69,186 shares during the period. 66.32% of the stock is currently owned by institutional investors and hedge funds.

WARNING: This story was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another domain, it was illegally stolen and republished in violation of United States and international trademark & copyright law. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/09/10/lemaitre-vascular-inc-lmat-shares-sold-by-blair-william-co-il.html.

In other news, Chairman George W. Lemaitre sold 58,700 shares of the firm’s stock in a transaction on Thursday, August 3rd. The stock was sold at an average price of $33.97, for a total transaction of $1,994,039.00. Following the transaction, the chairman now owns 3,471,808 shares in the company, valued at $117,937,317.76. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Lawrence J. Jasinski sold 6,500 shares of the firm’s stock in a transaction on Tuesday, August 1st. The shares were sold at an average price of $34.47, for a total value of $224,055.00. Following the transaction, the director now owns 12,863 shares in the company, valued at approximately $443,387.61. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 373,121 shares of company stock worth $12,825,992. Insiders own 23.70% of the company’s stock.

LMAT has been the topic of a number of research analyst reports. Zacks Investment Research raised shares of LeMaitre Vascular from a “hold” rating to a “buy” rating and set a $38.00 price objective on the stock in a research report on Tuesday, August 1st. Stifel Nicolaus restated a “buy” rating and set a $32.00 target price (up previously from $29.00) on shares of LeMaitre Vascular in a report on Sunday, July 30th. Benchmark Co. upgraded shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a report on Friday, July 28th. BidaskClub cut shares of LeMaitre Vascular from a “strong-buy” rating to a “buy” rating in a report on Tuesday, July 25th. Finally, Canaccord Genuity cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating and set a $28.00 target price on the stock. in a report on Monday, July 10th. Five investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $30.17.

Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) opened at 37.60 on Friday. The company has a market cap of $715.23 million, a PE ratio of 53.71 and a beta of 0.67. The stock’s 50 day moving average is $33.99 and its 200-day moving average is $29.05. LeMaitre Vascular, Inc. has a one year low of $18.55 and a one year high of $37.90.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings results on Thursday, July 27th. The medical instruments supplier reported $0.23 EPS for the quarter, beating the consensus estimate of $0.17 by $0.06. The firm had revenue of $25.80 million for the quarter, compared to analyst estimates of $25.42 million. LeMaitre Vascular had a return on equity of 15.02% and a net margin of 14.19%. The business’s revenue for the quarter was up 15.2% on a year-over-year basis. During the same quarter last year, the firm posted $0.14 earnings per share. Equities research analysts expect that LeMaitre Vascular, Inc. will post $0.80 earnings per share for the current year.

The company also recently declared a quarterly dividend, which was paid on Thursday, September 7th. Stockholders of record on Wednesday, August 23rd were paid a dividend of $0.055 per share. The ex-dividend date of this dividend was Monday, August 21st. This represents a $0.22 annualized dividend and a dividend yield of 0.59%. LeMaitre Vascular’s dividend payout ratio is currently 31.88%.

LeMaitre Vascular declared that its Board of Directors has approved a stock repurchase plan on Thursday, July 27th that permits the company to buyback $7.50 million in outstanding shares. This buyback authorization permits the medical instruments supplier to reacquire up to 1.4% of its stock through open market purchases. Stock buyback plans are typically an indication that the company’s management believes its stock is undervalued.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.

Want to see what other hedge funds are holding LMAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LeMaitre Vascular, Inc. (NASDAQ:LMAT).

Institutional Ownership by Quarter for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Stock Ratings for LeMaitre Vascular Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular Inc. and related stocks with our FREE daily email newsletter.